X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
INNO-206 (aldoxorubicin) is a prodrug of doxorubicin that binds endogenous albumin after administration. The bound doxorubicin is released in the acidic environment of the tumor cell through cleavage of an acid sensitive linker and expresses antitumor efficacy and toxicity.
Lead Product(s): Aldoxorubicin
Therapeutic Area: Oncology Product Name: INNO-206
Highest Development Status: Phase IIProduct Type:
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
Aldoxorubicin, a rationally-engineered cytotoxic delivers well-established anti-cancer agent, doxorubicin, into tumor, utilizes an acid-sensitive linker that selectively binds to albumin, which may allow cytotoxic payload to preferentially accumulate in tumor.
Lead Product(s): Aldoxorubicin
Therapeutic Area: Oncology Product Name: INNO-206
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
Through the merger with Centurion, the next-generation LADR drugs including INNO-206, are now within CytRx and poised for the last steps required for first-in-human studies, an achievement that could be expected to generate significant value for shareholders.
Lead Product(s): Aldoxorubicin
Therapeutic Area: Oncology Product Name: INNO-206
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CytRx Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 09, 2022
Details:
CytRx partner immunitybio announces the initiation of a Phase 2 registrational-intent study of its immunotherapy including aldoxorubicin in metastatic pancreatic cancer.
Lead Product(s): Aldoxorubicin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020
Details:
CytRx out-licensed global development, manufacturing, and commercialization rights for aldoxorubicin to ImmunityBio Inc. in July 2017.
Lead Product(s): Aldoxorubicin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: ImmunityBio
Deal Size: $343.0 million Upfront Cash: Undisclosed
Deal Type: Agreement January 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
